

**EXECUTIVE SUMMARY**

**REPORT TO THE BOARD OF DIRECTORS**

**BEING HELD ON 27 SEPTEMBER 2022**

<b>Subject</b>	Cancer recovery
<b>Supporting TEG Member</b>	Mark Tuckett, Director of Strategy & Planning
<b>Author</b>	Mark Tuckett
<b>Status<sup>1</sup></b>	N & A

**PURPOSE OF THE REPORT**

To update the board on our latest Cancer Waiting Time performance, and work that is underway to recover our position

**KEY POINTS**

- The Trust has historically had relatively good performance record for several of the national cancer waiting times. However, like other NHS providers, performance has been adversely affected by the restrictions placed on activity due to COVID-19 and now the significant increase in demand for cancer care on top of recovering the paused care from the past two years.
- National shortages in staffing across a number of professions which support the cancer pathways is one of major issues we are facing in terms of our ability to recover performance nationally and at our Trust.
- As a tertiary centre for cancer care we are responsible for delivering specialist care to a wider catchment than just Sheffield and so are impacted by the performance and timeliness of referrals from our partner referring hospitals. This means that a system wide response to reducing waiting times will be necessary and discussions are underway.
- Delivering improvements in cancer waiting times presents a significant and growing challenge but it is one which is identified as a key priority and recovery actions are underway and being overseen by the Trust Executive Group.
- The impact on waiting times for patients is the key driver to make further improvements as quickly as possible although the scale and complexity of the challenge cannot be underestimated as outlined in these slides.
- The Board agreed at its July Board of Directors meeting to discuss our cancer recovery on a monthly basis, due to our challenging position on Cancer Waiting Times and cancer performance more generally
- The accompanying set of slides updates the Board about:
  - Our latest performance for cancer waiting times
  - Our trajectory to recover performance
  - An overview of actions we are taking to recover our position and next steps

**IMPLICATIONS<sup>2</sup>**

<b>Aim of the STHFT Corporate Strategy</b>		<b>✓ Tick as appropriate</b>
1	Deliver the Best Clinical Outcomes	✓
2	Provide Patient Centred Services	✓
3	Employ Caring and Cared for Staff	✓

4	Spend Public Money Wisely	
5	Create a Sustainable Organisation	
6	Deliver Excellent Research, Education & Innovation	✓

## RECOMMENDATIONS

The Board is asked to note the latest position on cancer wait times; and work underway to recover our position.  
The Board is asked to agree to monthly updates to Finance and Performance Committee; with a quarterly update to the full board

## APPROVAL PROCESS

Meeting	Date	Approved Y/N
TEG	21 / 9 / 22	Y
Board of Directors	27 / 9 / 22	

<sup>1</sup> Status: A = Approval  
A\* = Approval & Requiring Board Approval  
D = Debate  
N = Note

<sup>2</sup> Against the six aims of the STHFT Corporate Strategy 'Making a Difference – The next Chapter 2022-27'